Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, Berlin, Germany ; Global Drug Discovery - Animal Health - Parasiticides, Bayer HealthCare, Leverkusen, Germany.
Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität Berlin, Berlin, Germany.
PLoS Negl Trop Dis. 2014 Feb 20;8(2):e2698. doi: 10.1371/journal.pntd.0002698. eCollection 2014 Feb.
The genus Trichuris includes parasites of major relevance in veterinary and human medicine. Despite serious economic losses and enormous impact on public health, treatment options against whipworms are very limited. Additionally, there is an obvious lack of appropriately characterized experimental infection models. Therefore, a detailed parasitological characterization of a Trichuris muris isolate was performed in C57BL/10 mice. Subsequently, the in vivo efficacies of the aminophenylamidines amidantel, deacylated amidantel (dAMD) and tribendimidine as well as the cyclooctadepsipeptides emodepside and in particular PF1022A were analyzed. This was performed using various administration routes and treatment schemes targeting histotropic and further developed larval as well as immature and mature adult stages.
METHODOLOGY/PRINCIPAL FINDINGS: Duration of prepatent period, time-dependent localization of larvae during period of prepatency as well as the duration of patency of the infection were determined before drugs were tested in the characterized trichurosis model. Amidantel showed no effect against mature adult T. muris. Tribendimidine showed significantly higher potency than dAMD after oral treatments (ED50 values of 6.5 vs. 15.1 mg/kg). However, the opposite was found for intraperitoneal treatments (ED50 values of 15.3 vs. 8.3 mg/kg). When emodepside and PF1022A were compared, the latter was significantly less effective against mature adults following intraperitoneal (ED50 values of 6.1 vs. 55.7 mg/kg) or subcutaneous (ED50 values of 15.2 vs. 225.7 mg/kg) administration. Only minimal differences were observed following oral administration (ED50 values of 2.7 vs. 5.2 mg/kg). Triple and most single oral doses with moderate to high dosages of PF1022A showed complete efficacy against histotropic second stage larvae (3 × 100 mg/kg or 1 × 250 mg/kg), further developed larvae (3 × 10 mg/kg or 1 × 100 mg/kg) and immature adults (3 × 10 mg/kg or 1×100 mg/kg). Histotropic first stage larvae were only eliminated after three doses of PF1022A (3 × 100 mg/kg) but not after a single dose.
CONCLUSIONS/SIGNIFICANCE: These results indicate that the cyclooctadepsipeptides are a drug class with promising candidates for further evaluation for the treatment of trichurosis of humans and livestock animals in single dose regimens.
旋毛虫属包括兽医和人类医学中具有重要意义的寄生虫。尽管造成了严重的经济损失,并对公众健康产生了巨大影响,但针对鞭虫的治疗选择非常有限。此外,显然缺乏经过适当特征描述的实验感染模型。因此,对 C57BL/10 小鼠中的一株旋毛虫分离株进行了详细的寄生虫学特征描述。随后,分析了氨基苯酰胺类 amidantel、去酰化 amidantel(dAMD)和三苯双脒以及环辛二肽类 emodepside 和特别是 PF1022A 在体内的疗效,这些药物针对组织嗜性以及进一步发育的幼虫以及未成熟和成熟的成虫阶段,采用了各种给药途径和治疗方案。
方法/主要发现:在该特征性的旋毛虫病模型中测试药物之前,确定了无脊椎动物前潜伏期、无脊椎动物前潜伏期期间幼虫的时间依赖性定位以及感染的无脊椎动物前潜伏期的持续时间。amidantel 对成熟的旋毛虫成虫没有作用。三苯双脒经口服治疗后的效力明显高于 dAMD(ED50 值分别为 6.5 和 15.1mg/kg)。然而,腹腔内治疗时却发现相反的结果(ED50 值分别为 15.3 和 8.3mg/kg)。当比较 emodepside 和 PF1022A 时,后者经腹腔内(ED50 值分别为 6.1 和 55.7mg/kg)或皮下(ED50 值分别为 15.2 和 225.7mg/kg)给药时对成熟成虫的效果明显较差。经口服给药时仅观察到微小差异(ED50 值分别为 2.7 和 5.2mg/kg)。中等至高剂量的 PF1022A 进行三联或单一口服剂量,对组织嗜性的第二期幼虫(3×100mg/kg 或 1×250mg/kg)、进一步发育的幼虫(3×10mg/kg 或 1×100mg/kg)和未成熟成虫(3×10mg/kg 或 1×100mg/kg)具有完全疗效。组织嗜性的第一期幼虫仅在 PF1022A 进行三剂治疗(3×100mg/kg)后被消除,但一剂治疗后不能消除。
结论/意义:这些结果表明,环辛二肽类是一类具有前途的候选药物,可在单次剂量方案中进一步评估治疗人类和家畜旋毛虫病。